Competitive Technologies (OTCMKTS:CTTC) and Nuwellis (NASDAQ:NUWE) Critical Analysis

Competitive Technologies (OTCMKTS:CTTC) and Nuwellis (NASDAQ:NUWE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Earnings & Valuation

This table compares Competitive Technologies and Nuwellis”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Competitive Technologies	N/A	N/A	N/A	N/A	N/A
Nuwellis	$8.27 million	1.07	-$17.52 million	($64.02)	-0.05

Competitive Technologies has higher earnings, but lower revenue than Nuwellis.

Analyst Recommendations

This is a breakdown of current ratings for Competitive Technologies and Nuwellis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Competitive Technologies	0	0	0	0	0.00
Nuwellis	1	0	0	0	1.00

Given Competitive Technologies’ higher probable upside, equities analysts clearly believe Competitive Technologies is more favorable than Nuwellis.

Profitability

This table compares Competitive Technologies and Nuwellis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Competitive Technologies	N/A	N/A	N/A
Nuwellis	-214.90%	-32,351.83%	-249.08%

Insider & Institutional Ownership

3.1% of Nuwellis shares are held by institutional investors. 17.5% of Competitive Technologies shares are held by insiders. Comparatively, 1.6% of Nuwellis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Competitive Technologies beats Nuwellis on 5 of the 8 factors compared between the two stocks.

About Competitive Technologies

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.

About Nuwellis

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.